688180 君实生物
已收盘 01-14 15:00:00
资讯
新帖
简况
君实生物跌1.3% 连亏9年3季2020年上市2募资共86亿
中金财经 · 01-12 17:23
君实生物跌1.3% 连亏9年3季2020年上市2募资共86亿
每周股票复盘:君实生物(688180)董事长增持A股10万股耗资383.84万元
证券之星 · 01-11
每周股票复盘:君实生物(688180)董事长增持A股10万股耗资383.84万元
君实生物:公司董事长熊俊先生的增持计划尚未实施完毕
证券日报 · 01-07
君实生物:公司董事长熊俊先生的增持计划尚未实施完毕
上海君实生物医药科技股份有限公司发布2025年12月证券变动月报,总股本及已发行股份数维持稳定
中金财经 · 01-06
上海君实生物医药科技股份有限公司发布2025年12月证券变动月报,总股本及已发行股份数维持稳定
每周股票复盘:君实生物(688180)募投项目延期至2028年
证券之星 · 01-02
每周股票复盘:君实生物(688180)募投项目延期至2028年
每周股票复盘:君实生物(688180)获准注册20亿元中期票据
证券之星 · 2025-12-28
每周股票复盘:君实生物(688180)获准注册20亿元中期票据
君实生物:20亿元中期票据获批注册
财中社 · 2025-12-25
君实生物:20亿元中期票据获批注册
君实生物:上海檀英拟减持不超2%股份
每日经济新闻 · 2025-12-18
君实生物:上海檀英拟减持不超2%股份
乐普医疗:截至目前未持有君实生物股份
证券之星 · 2025-12-16
乐普医疗:截至目前未持有君实生物股份
君实生物(01877.HK)涨超4%
每日经济新闻 · 2025-12-15
君实生物(01877.HK)涨超4%
港股异动 | 君实生物(01877)涨超4% JS212用于治疗晚期实体瘤临床试验申请获FDA批准
智通财经 · 2025-12-15
港股异动 | 君实生物(01877)涨超4% JS212用于治疗晚期实体瘤临床试验申请获FDA批准
君实生物:JS212临床试验申请获得FDA批准
证券之星 · 2025-12-14
君实生物:JS212临床试验申请获得FDA批准
君实生物: JS207目前处于II期临床研究阶段
每日经济新闻 · 2025-12-10
君实生物: JS207目前处于II期临床研究阶段
君实生物控股股东兼董事长熊俊已增持10万股
财中社 · 2025-12-10
君实生物控股股东兼董事长熊俊已增持10万股
港股异动 | 君实生物(01877)早盘涨超3% 拓益®2项新增适应症和君适达®纳入国家医保目录
智通财经 · 2025-12-08
港股异动 | 君实生物(01877)早盘涨超3% 拓益®2项新增适应症和君适达®纳入国家医保目录
君实生物:自愿披露关于偌考奇拜单抗注射液新药上市申请获得受理的公告
证券日报 · 2025-12-07
君实生物:自愿披露关于偌考奇拜单抗注射液新药上市申请获得受理的公告
君实生物:拓益®新增适应症和君适达®纳入国家医保目录
证券之星 · 2025-12-07
君实生物:拓益®新增适应症和君适达®纳入国家医保目录
君实生物抗IL-17A单抗银屑病新药上市申请获受理
中金财经 · 2025-12-07
君实生物抗IL-17A单抗银屑病新药上市申请获受理
君实生物宣布罗坎那帕(Roconkibart)的新药申请获得接受,用于治疗中度至重度斑块型银屑病
美股速递 · 2025-12-05
君实生物宣布罗坎那帕(Roconkibart)的新药申请获得接受,用于治疗中度至重度斑块型银屑病
君实生物(688180.SH):偌考奇拜单抗注射液新药上市申请获得受理
智通财经 · 2025-12-05
君实生物(688180.SH):偌考奇拜单抗注射液新药上市申请获得受理
加载更多
公司概况
公司名称:
上海君实生物医药科技股份有限公司
所属行业:
医药制造业
上市日期:
2020-07-15
主营业务:
上海君实生物医药科技股份有限公司的主营业务是创新药物的发现和开发、在全球范围内的临床研究、大规模生产到商业化的全产业链。公司的主要产品是以源头创新、自主研发类生物制品为主,同时通过合作开发、设立合资企业以及许可(license-in)等形式引进与自有源创产品线有协同作用的药物或平台技术,进一步壮大产品管线。曾荣膺国家专利领域最高奖项“中国专利金奖”,并获得“十二五”、“十三五”两项“重大新药创制”国家重大科技专项支持。
发行价格:
55.50
{"stockData":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物","latestPrice":38.42,"timestamp":1768374000000,"preClose":39.35,"halted":0,"volume":17404329,"delay":0,"changeRate":-0.0236,"floatShares":766000000,"shares":1027000000,"eps":-0.9252,"marketStatus":"已收盘","change":-0.93,"latestTime":"01-14 15:00:00","open":39.05,"high":39.82,"low":37.82,"amount":678000000,"amplitude":0.0508,"askPrice":38.43,"askSize":87,"bidPrice":38.42,"bidSize":20,"shortable":0,"etf":0,"ttmEps":-0.9252,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768440600000},"marketStatusCode":5,"adr":0,"adjPreClose":39.35,"symbolType":"stock_kcb","openAndCloseTimeList":[[1768354200000,1768361400000],[1768366800000,1768374000000]],"highLimit":43.29,"lowLimit":35.42,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1026689871,"isCdr":false,"pbRate":6.35,"roa":"--","roe":"--","epsLYR":-1.3,"committee":0.474729,"marketValue":39445000000,"turnoverRate":0.0227,"status":1,"afterMarket":{"amount":0,"volume":0,"close":38.42,"buyVolume":0,"sellVolume":0,"time":1768376037558,"indexStatus":"已收盘 01-14 15:30:00","preClose":39.35},"hkstockBrief":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"君实生物","latestPrice":24.5,"timestamp":1768378086004,"preClose":24.06,"halted":0,"volume":4093587,"delay":0,"premium":"-42.98"},"floatMarketCap":29445000000},"requestUrl":"/m/hq/s/688180","defaultTab":"news","newsList":[{"id":"2602518361","title":"君实生物跌1.3% 连亏9年3季2020年上市2募资共86亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2602518361","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602518361?lang=zh_cn&edition=full","pubTime":"2026-01-12 17:23","pubTimestamp":1768209784,"startTime":"0","endTime":"0","summary":"中国经济网北京1月12日讯 君实生物 今日收报38.69元,跌幅1.30%。该股目前处于破发状态。 上市首日,君实生物股价最高报220.40元,为上市以来股价最高点。 君实生物首次公开发行股票募集资金总额为48.36亿元,扣除发行费用后,募集资金净额为44.97亿元,较原计划多17.97亿元。 君实生物首次公开发行股票募的发行费用为3.39亿元,其中,保荐及承销费用3.20亿元。实际到账金额为人民币3,759,350,000.00元,包括尚未支付的其他发行费用人民币14,547,205.06元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260112/31934705.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688180","BK1161","BK1515","01877","BK0239","BK1583"],"gpt_icon":0},{"id":"2602533190","title":"每周股票复盘:君实生物(688180)董事长增持A股10万股耗资383.84万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602533190","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602533190?lang=zh_cn&edition=full","pubTime":"2026-01-11 01:53","pubTimestamp":1768067589,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘,君实生物报收于39.2元,较上周的34.16元上涨14.75%。截至2026年1月10日,熊俊通过集中竞价方式累计增持A股100,000股,约占总股本0.01%,累计成交金额383.84万元。本次增持计划尚未实施完毕,熊俊将继续择机增持。君实生物H股公告显示,截至2025年12月31日,公司H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。H股总数为260,295,700股,在香港联交所上市;A股总数为766,394,171股,在上海证券交易所科创板上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","BK1161","BK0239","BK1515","BK1583","399300","159982","688180"],"gpt_icon":0},{"id":"2601776758","title":"君实生物:公司董事长熊俊先生的增持计划尚未实施完毕","url":"https://stock-news.laohu8.com/highlight/detail?id=2601776758","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601776758?lang=zh_cn&edition=full","pubTime":"2026-01-07 19:38","pubTimestamp":1767785928,"startTime":"0","endTime":"0","summary":"证券日报网讯1月7日,君实生物在互动平台回答投资者提问时表示,截至本回复日,公司董事长熊俊先生的增持计划尚未实施完毕,熊俊先生将在增持计划实施期间内择机增持公司股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601073611635637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK1583","BK1515","688180","BK1161","01877"],"gpt_icon":0},{"id":"2601852542","title":"上海君实生物医药科技股份有限公司发布2025年12月证券变动月报,总股本及已发行股份数维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=2601852542","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601852542?lang=zh_cn&edition=full","pubTime":"2026-01-06 10:16","pubTimestamp":1767665776,"startTime":"0","endTime":"0","summary":"中访网数据 上海君实生物医药科技股份有限公司于2026年1月5日向香港交易及结算所有限公司提交了截至2025年12月31日的证券变动月报表。报告显示,公司在报告期内股本结构保持稳定,未发生已发行股份及库存股份的变动。具体而言,H股已发行股份为260,295,700股,A股已发行股份为766,394,171股。 综上所述,上海君实生物在2025年12月未进行新股发行、股份回购或库存股份转让,总股本及股权激励计划下的潜在股份发行数量均保持不变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260106/31918345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159938","BK1161","BK1583","161027","BK1515","BK1574","688180","BK0239","09939","01877"],"gpt_icon":0},{"id":"2600035453","title":"每周股票复盘:君实生物(688180)募投项目延期至2028年","url":"https://stock-news.laohu8.com/highlight/detail?id=2600035453","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600035453?lang=zh_cn&edition=full","pubTime":"2026-01-02 01:59","pubTimestamp":1767290347,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,君实生物报收于34.99元,较上周的35.41元下跌1.19%。国泰海通证券股份有限公司关于上海君实生物医药科技股份有限公司募集资金投资项目延期的核查意见君实生物因项目实际进展需要,拟将2022年度向特定对象发行A股股票的募投项目实施期限进行调整。创新药研发项目实施期限由2025年12月延期至2028年12月,上海君实生物科技总部及研发基地项目由2025年12月延期至2026年6月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688180","BK1515","01877","BK1161","BK1583","BK0239"],"gpt_icon":0},{"id":"2594244012","title":"每周股票复盘:君实生物(688180)获准注册20亿元中期票据","url":"https://stock-news.laohu8.com/highlight/detail?id=2594244012","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594244012?lang=zh_cn&edition=full","pubTime":"2025-12-28 03:26","pubTimestamp":1766863572,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,君实生物报收于34.99元,较上周的35.41元下跌1.19%。本周,君实生物12月23日盘中最高价报35.49元。本周关注点公司公告汇总:君实生物收到交易商协会通知,科技创新债券注册获受理,注册金额为20亿元。注册品种为中期票据,注册金额为20亿元,注册额度自通知书落款之日起2年内有效,由上海银行股份有限公司主承销。公司将根据授权及监管要求择机实施发行,并履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688180","BK1161","01877","BK0239","BK1583","BK1515"],"gpt_icon":0},{"id":"2594236952","title":"君实生物:20亿元中期票据获批注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2594236952","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594236952?lang=zh_cn&edition=full","pubTime":"2025-12-25 17:38","pubTimestamp":1766655481,"startTime":"0","endTime":"0","summary":"12月25日,君实生物(688180/01877)发布公告,中国银行间市场交易商协会决定接受公司科技创新债券注册。此次注册的基础品种为中期票据,注册金额为20亿元,注册额度自通知书落款之日起2年内有效,主承销商为上海银行(601229)。2025年前三季度,君实生物实现收入18.06亿元,归母净利润-5.96亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601959357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1583","01877","688180","BK1515","BK0239"],"gpt_icon":0},{"id":"2592087977","title":"君实生物:上海檀英拟减持不超2%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2592087977","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592087977?lang=zh_cn&edition=full","pubTime":"2025-12-18 19:03","pubTimestamp":1766055835,"startTime":"0","endTime":"0","summary":"每经AI快讯,12月18日,君实生物(688180.SH)公告称,持股5%以上股东上海檀英因基金期限与流动性资金安排,计划通过大宗交易方式减持其持有的公司股份不超过2053.38万股,占公司总股本的2%。减持期间为2026年1月13日至2026年4月10日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512183595608583.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512183595608583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01877","688180","BK1583","BK1515","BK1161","BK0239"],"gpt_icon":0},{"id":"2591602616","title":"乐普医疗:截至目前未持有君实生物股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2591602616","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591602616?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:36","pubTimestamp":1765874181,"startTime":"0","endTime":"0","summary":"证券之星消息,乐普医疗(300003)12月16日在投资者关系平台上答复投资者关心的问题。投资者提问:公司及其关联方持有多少君实生物股份?谢谢乐普医疗回复:尊敬的投资者,您好!截至目前,本公司及关联方并未持有任何君实生物(股票代码:01877.HK/688180.SH)的股份。感谢您的关心。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600024809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","BK0113","BK0188","300003","BK1161","BK0239","BK1515","BK1583","BK0251","BK0042","BK0196","BK0201","688180","BK0114","BK0028"],"gpt_icon":0},{"id":"2591696977","title":"君实生物(01877.HK)涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591696977","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591696977?lang=zh_cn&edition=full","pubTime":"2025-12-15 10:02","pubTimestamp":1765764134,"startTime":"0","endTime":"0","summary":"每经AI快讯,君实生物(01877.HK)涨超4%,截至发稿涨4.33%,报25港元,成交额3483.03万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512153591485475.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153591485475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK0239","688180","BK1583","BK1515","01877"],"gpt_icon":0},{"id":"2591695413","title":"港股异动 | 君实生物(01877)涨超4% JS212用于治疗晚期实体瘤临床试验申请获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2591695413","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591695413?lang=zh_cn&edition=full","pubTime":"2025-12-15 09:46","pubTimestamp":1765763185,"startTime":"0","endTime":"0","summary":"消息面上,12月14日,君实生物发布公告,本公司收到美国食品药品监督管理局的通知,EGFR/HER3双特异性抗体偶联药物用于治疗晚期实体瘤的临床试验申请获得FDA批准。截至本公告日期,JS212正在中国内地开展一项开放标签、剂量递增和剂量扩展的I/II期临床试验,旨在晚期实体瘤患者中评估JS212的安全性、耐受性、药代动力学和初步疗效。此外,JS212多队列联合用药的临床试验申请已于2025年11月获得国家药监局批准,计划于近期开展相关临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688180","01877","BK1161","BK0239","BK1583","BK1515"],"gpt_icon":0},{"id":"2591657766","title":"君实生物:JS212临床试验申请获得FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2591657766","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591657766?lang=zh_cn&edition=full","pubTime":"2025-12-14 15:50","pubTimestamp":1765698622,"startTime":"0","endTime":"0","summary":"君实生物(688180.SH)公告称,公司收到FDA通知,EGFR/HER3双特异性抗体偶联药物JS212用于治疗晚期实体瘤的临床试验申请获得FDA批准。JS212主要用于晚期恶性实体瘤的治疗,与单一靶点ADC药物相比,有望对更广泛的肿瘤有效,同时有望克服耐药性问题。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121400001561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688180","BK1161","BK0239","01877","BK1515","BK1583"],"gpt_icon":0},{"id":"2590258535","title":"君实生物: JS207目前处于II期临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2590258535","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590258535?lang=zh_cn&edition=full","pubTime":"2025-12-10 18:03","pubTimestamp":1765361035,"startTime":"0","endTime":"0","summary":"每经AI快讯,有投资者在投资者互动平台提问:请问公司目前是否有JS207(PD-1/VEGF双抗)与JS212(EGFR/HER3双抗ADC)联合临床实验在推进,或者有该联合方案的计划,如果有,能否介绍一下目前进展情况?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512103587782740.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512103587782740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","01877","688180","BK1161","BK1583","BK1515"],"gpt_icon":0},{"id":"2590583171","title":"君实生物控股股东兼董事长熊俊已增持10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590583171","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590583171?lang=zh_cn&edition=full","pubTime":"2025-12-10 17:51","pubTimestamp":1765360274,"startTime":"0","endTime":"0","summary":"12月10日,君实生物(688180/01877)发布公告,控股股东兼董事长熊俊自2025年4月12日起计划在12个月内增持公司股份,已通过集中竞价增持10万股A股,累计增持金额为384万元。2025年前三季度,君实生物实现收入18.06亿元,归母净利润-5.96亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512103587770478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK1161","BK1583","01877","BK1515","688180"],"gpt_icon":0},{"id":"2589380761","title":"港股异动 | 君实生物(01877)早盘涨超3% 拓益®2项新增适应症和君适达®纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589380761","media":"智通财经","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589380761?lang=zh_cn&edition=full","pubTime":"2025-12-08 09:32","pubTimestamp":1765157546,"startTime":"0","endTime":"0","summary":"新版国家医保目录将于2026年1月1日起正式实施。拓益已在中国内地获批上市的12项适应症全部纳入国家医保目录,是目录中唯一用于肾癌、三阴性乳腺癌和黑色素瘤治疗的抗PD-1单抗药物;君适达为首次纳入,是新版目录中唯一用于他汀不耐受人群的国产PCSK9靶点药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378594.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","688180","BK1161","01877","BK0239","BK1583"],"gpt_icon":0},{"id":"2589891877","title":"君实生物:自愿披露关于偌考奇拜单抗注射液新药上市申请获得受理的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2589891877","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589891877?lang=zh_cn&edition=full","pubTime":"2025-12-07 20:37","pubTimestamp":1765111021,"startTime":"0","endTime":"0","summary":"证券日报网讯12月5日晚间,君实生物发布公告称,近日,公司收到国家药品监督管理局核准签发的《受理通知书》,公司产品偌考奇拜单抗注射液(重组人源化抗IL-17A单克隆抗体注射液,产品代号:JS005)用于治疗适合系统治疗或光疗的中度至重度斑块状银屑病的成人患者的新药上市申请获得受理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512073584622992.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","01877","BK0239","BK1161","688180","BK1515"],"gpt_icon":0},{"id":"2589784876","title":"君实生物:拓益®新增适应症和君适达®纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589784876","media":"证券之星","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589784876?lang=zh_cn&edition=full","pubTime":"2025-12-07 15:40","pubTimestamp":1765093209,"startTime":"0","endTime":"0","summary":"君实生物公告称,公司产品特瑞普利单抗注射液2项新增适应症和昂戈瑞西单抗注射液成功纳入《国家基本医疗保险、生育保险和工伤保险药品目录》乙类范围。新版国家医保目录将于2026年1月1日起正式实施。拓益已在中国内陆获批的12项适应症全部纳入国家医保目录,是目录中唯一用于肾癌、三阴性乳腺癌和黑色素瘤治疗的抗PD-1单抗药物;君适达为首次纳入,是新版目录中唯一用于他汀不耐受人群的国产PCSK9靶点药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120700002591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","BK1583","01877","BK1515","688180"],"gpt_icon":0},{"id":"2589928878","title":"君实生物抗IL-17A单抗银屑病新药上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2589928878","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589928878?lang=zh_cn&edition=full","pubTime":"2025-12-07 10:38","pubTimestamp":1765075080,"startTime":"0","endTime":"0","summary":"中访网数据 上海君实生物医药科技股份有限公司今日宣布,其自主研发的创新药偌考奇拜单抗注射液用于治疗中重度斑块状银屑病的新药上市申请,已获得国家药品监督管理局受理。该药物是一款重组人源化抗IL-17A单克隆抗体,通过阻断炎症信号通路发挥作用。若获批上市,偌考奇拜单抗将为该患者群体提供新的治疗选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251207/31849162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","BK1515","688180","BK1583","01877","BK1161"],"gpt_icon":0},{"id":"1148486256","title":"君实生物宣布罗坎那帕(Roconkibart)的新药申请获得接受,用于治疗中度至重度斑块型银屑病","url":"https://stock-news.laohu8.com/highlight/detail?id=1148486256","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148486256?lang=zh_cn&edition=full","pubTime":"2025-12-05 23:20","pubTimestamp":1764948013,"startTime":"0","endTime":"0","summary":"君实生物宣布罗坎那帕(Roconkibart)的新药申请获得接受,用于治疗中度至重度斑块型银屑病","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688180"],"gpt_icon":0},{"id":"2589189805","title":"君实生物(688180.SH):偌考奇拜单抗注射液新药上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2589189805","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589189805?lang=zh_cn&edition=full","pubTime":"2025-12-05 17:27","pubTimestamp":1764926866,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物 发布公告,近日,公司收到国家药品监督管理局核准签发的《受理通知书》,公司产品偌考奇拜单抗注射液用于治疗适合系统治疗或光疗的中度至重度斑块状银屑病的成人患者的新药上市申请获得受理。截至公告披露日,除本次新药上市申请外,偌考奇拜单抗用于治疗活动性强直性脊柱炎的Ⅱ期临床研究的所有参与者已完成治疗,进入安全随访期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01877","688180","BK1583","BK1515","BK0239","BK1161"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768392561745,"stockEarnings":[{"period":"1week","weight":0.0722},{"period":"1month","weight":0.0757},{"period":"3month","weight":0.0239},{"period":"6month","weight":-0.0078},{"period":"1year","weight":0.5437},{"period":"ytd","weight":0.1519}],"compareEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":0.0641},{"period":"3month","weight":0.0579},{"period":"6month","weight":0.1768},{"period":"1year","weight":0.3094},{"period":"ytd","weight":0.0428}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海君实生物医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"35877人(较上一季度增加15.17%)","perCapita":"21361股","listingDate":"2020-07-15","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路987号4层","registeredCapital":"102668万元","survey":" 上海君实生物医药科技股份有限公司的主营业务是创新药物的发现和开发、在全球范围内的临床研究、大规模生产到商业化的全产业链。公司的主要产品是以源头创新、自主研发类生物制品为主,同时通过合作开发、设立合资企业以及许可(license-in)等形式引进与自有源创产品线有协同作用的药物或平台技术,进一步壮大产品管线。曾荣膺国家专利领域最高奖项“中国专利金奖”,并获得“十二五”、“十三五”两项“重大新药创制”国家重大科技专项支持。","listedPrice":55.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(688180)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(688180)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,688180,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(688180)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(688180)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}